Members of the Cbl family of intracellular proteins, c-Cbl and Cbl-b are prominent substrates for tyrosine phosphorylation in immune cells [1, 2] . At least four Cbl family members have been described: c-Cbl, the related protein Cbl-b, Caenorhabditis elegans Cbl (Sli-1) and Drosophila Cbl (D-Cbl) (Figure 1) . Cbl is the mammalian ortholog of Sli-1 of C. elegans, and was originally noted for its negative regulation of signaling downstream of v-ErbB, the oncogenic form of the epidermal growth factor receptor. In the immune system, c-Cbl profoundly inhibits the function of T, B and mast cells by downregulating kinases such as . While past studies have linked c-Cbl to protein turnover, the precise molecular basis for Cbl function has only recently become evident with the discovery that Cbl can recruit components of the ubiquitinconjugation pathway [6] [7] [8] and act as an ubiquitin-protein ligase [9] . Furthermore, two new papers describing Cbl-bdeficient mice reveal a provocative connection between Cbl-b-mediated protein degradation and the regulation of the threshold of T-and B-cell signaling leading to the development of autoimmunity [10, 11] .
Members of the Cbl family of intracellular proteins, c-Cbl and Cbl-b are prominent substrates for tyrosine phosphorylation in immune cells [1, 2] . At least four Cbl family members have been described: c-Cbl, the related protein Cbl-b, Caenorhabditis elegans Cbl (Sli-1) and Drosophila Cbl (D-Cbl) ( Figure 1 ). Cbl is the mammalian ortholog of Sli-1 of C. elegans, and was originally noted for its negative regulation of signaling downstream of v-ErbB, the oncogenic form of the epidermal growth factor receptor. In the immune system, c-Cbl profoundly inhibits the function of T, B and mast cells by downregulating kinases such as Zap-70 and Syk [3] [4] [5] [6] . While past studies have linked c-Cbl to protein turnover, the precise molecular basis for Cbl function has only recently become evident with the discovery that Cbl can recruit components of the ubiquitinconjugation pathway [6] [7] [8] and act as an ubiquitin-protein ligase [9] . Furthermore, two new papers describing Cbl-bdeficient mice reveal a provocative connection between Cbl-b-mediated protein degradation and the regulation of the threshold of T-and B-cell signaling leading to the development of autoimmunity [10, 11] .
Cbl as a ubiquitin ligase
Ubiquitination is a process by which cells can discriminate and target specific proteins for degradation from a vast array of intracellular constituents and surface proteins. It is regulated by a series of enzymes (termed E1, E2, E3 and E4) that, in several cyclic steps, transfer the 8,565 Da ubiquitin polypeptide to a host protein, tagging it for degradation by the 26S proteasome (Figure 2a ). The process is initiated by the E1 ubiquitin-activating enzymes that mediate the ATP-dependent charging of ubiquitin with the formation of a thioester bond between a cysteine residue in the E1 enzyme and the carboxyl terminus of ubiquitin. This high-energy bond is then transferred to the E2 ubiquitin-conjugating enzymes, which, either by themselves or in conjunction with E3 ubiquitin-protein ligases, transfer ubiquitin monomers or polymers to target substrates. Polyubiquitin chain synthesis can be increased by other factors, such as E4 proteins, and decreased by deubiquitinating proteases. Eventually, ubiquitin-tagged polypeptides are degraded into peptides by the 26S proteasome. Although the exact mechanism responsible for selectivity of substrates is not known, each of the E1, E2 and E3 enzymes are encoded by genes comprising a supergene family, thereby providing specificity amongst the different isoforms. The full range of enzymes and their specificities are only just beginning to be elucidated.
Each of the Cbl proteins has a conserved phosphotyrosinebinding domain (PTB) and a small zinc-binding domain termed the RING finger domain, while c-Cbl and Cbl-b have an additional proline-rich region and multiple tyrosine phosphorylation sites (Figure 1 ). The different regions in Cbl cooperate to facilitate target selection and ubiquitination. While the PTB domain binds to specific phosphotyrosine motifs in target proteins, the RING finger recruits an E2 enzyme, which in this case is the human ubiquitinconjugating enzyme 7 (UbcH7) [8] . The RING finger itself acts as an E3 ligase and promotes conjugation of ubiquitin to the target substrate [9] . Cbl proteins therefore combine the specificity of PTB substrate selection with the RING finger E2-binding and ligase activity within a single protein (Figure 2b ). Mutant forms of Cbl that contain deletions (such as 70Z/cbl) or a point mutation (such as the cysteine to alanine mutation at position 381) are defective in promoting ubiquitination [1] (Figure 1) .
Ubiquitination sets the threshold of immune cell signaling
With their capacity to selectively degrade key intracellular proteins, c-Cbl and Cbl-b are ideally suited to negatively regulate aspects of immune cell function. Indeed, c-Cbl-deficient mice show hypercellularity of lymphoid organs and altered positive selection in the thymus, and cells from these mice show increased intracellular protein phosphorylation and surface receptor expression [1] . Two recent reports have provided exciting evidence for a more subtle role for Cbl-b in regulating the threshold of signaling in T and B cells [10, 11] . T cells from Cbl-bdeficient mice show enhanced proliferation and interleukin-2 (IL-2) production in response to triggering of the T-cell receptor, while B cells show potentiation of proliferation in response to B-cell receptor and CD40 triggering [10] .
In an extension of this phenotype, the lowering of the threshold caused by the loss of Cbl-b correlated with an increased susceptibility to the development of autoimmunity. These mice had an increased presence of autoantibodies reactive to double-stranded DNA and showed signs of spontaneous autoimmunity [10] , or an increased susceptibility to experimental autoimmune encephalomyelitis (a mouse model for multiple sclerosis) [11] . The difference in the onset of autoimmunity observed in these two studies could be related to the different genetic background or ages of the host mice, or to the presence of infectious reagents or to different environments. The important point is that both studies support the exciting notion that Cbl-b is a key regulator of the susceptibility to autoimmunity, findings with potential relevance to human autoimmune disorders, such as multiple sclerosis or type 1 diabetes.
Which intracellular protein targeted by Cbl-b could account for this phenotype? Many phosphoproteins associate with Cbl-b including phospholipase Cγ (PLCγ), phosphoinositol (PI) 3-kinase, the kinases Lck, Fyn, Zap-70 and Syk, and the adaptor proteins Slp-76 and Vav. Despite the many targets, Cbl-b-deficient cells showed a selective enhancement of Vav phosphorylation, indicating that Cblb is a negative regulator of the phosphorylation of this protein -an important finding, given that Vav is a key guanine nucleotide exchange factor for the Rho family of GTP-binding proteins (Rac1, Rac2 and Cdc42) in lymphoid cells. Vav guanine nucleotide exchange activity is upregulated by Lck-mediated phosphorylation (and possibly also by other kinases).
Further, the GTP-bound form of the Rac1 GTPase promotes actin polymerization, the organization of the cytoskeleton and receptor aggregation [12] . In accordance with this phenotype, the conversion of Rac1 to a GTPbound active form is enhanced in Cbl-b-deficient cells [11] . Paradoxically, despite its binding to Cbl-b, Vav itself is unlikely to be directly regulated by Cbl-b because its expression is unchanged in these cells. Instead, an upstream regulator of the Vav-Rac1 pathway is more likely to be responsible for the phenotype (Figure 3) . The identity of the upstream regulator is unclear, but it is presumably a regulatory factor (i.e. for localisation or inhibition of phosphatases) or a kinase other than Lck. In either case, a connection with the Vav-Rac 1 pathway is compatible with the central role of this pathway in actin-dependent T-cell receptor cap formation [13, 14] . In addition, T cells from Vav-deficient mice have been found to be impaired in T-cell receptor signaling [15, 16] . Mechanisms of ubiquitination. (a) Ubiquitination targets specific proteins for degradation. The process is regulated by a series of enzymes (termed E1, E2, E3 and E4) that, in cyclic steps, transfer the ubiquitin polypeptide to a host protein as a marker for degradation by the 26S proteasome. E1 SH (single ubiquitin-activating enzyme) catalyzes formation of a complex composed of a covalent E1S-ubiquitin (E1 S-Ub ) and non-covalently bound ubiquitin adenylate (AMP-Ub). E2 SH (ubiquitin-conjugating enzyme) catalyzes a transthiolation reaction leading to E2S-ubiquitin thiolester (E2 S-Ub ). E3 (ubiquitin-protein isopeptide ligase) binds the target protein and catalyzes isopeptide bond formation. (b) Cbl-mediated ubiquitination. The PTB domain binds to specific tyrosine-phosphorylated proteins, while the RING finger recruits the human E2 ubiquitin-conjugating enzyme 7 (UbcH7). As an E3 ligase, the RING finger can then facilitate ubiquitin conjugation to the target substrate.
Is Cbl-b linked to CD28 or T-cell receptor signaling pathways?
Given that Cbl-b alters the threshold requirements for signaling, the next key question was whether Cbl-b is linked to co-stimulation through the T-cell co-receptor CD28. Optimal T-cell activation requires two signals, one sent by the T-cell receptor and a second co-stimulatory signal from CD28 when bound to its ligands CD80 or CD86 [17] . Indeed, CD28 (and the related CTLA-4 molecule) is widely accepted as setting the threshold of signaling through the T-cell receptor complex. CD28 interacts with PI 3-kinase and the adaptors Grb2 and Vav, and can induce Vav phosphorylation (for reviews, see [18, 19] ). Mutations in the CD28 cytoplasmic tail can also cause a concomitant loss of Vav phosphorylation and co-stimulation [20] .
The most compelling evidence in support of a connection between Cbl-b and CD28-mediated co-stimulation is the observation in the recent studies that the loss of Cbl-b in CD28-deficient mice restores high levels of proliferation that are absent in T cells from Cbl-b +/+ CD28-deficient mice [10, 11] . This finding could be interpreted to indicate that the Cbl-b mutation uncouples proliferation from CD28, or that the loss of Cbl-b simply upregulates proliferation mediated by the T-cell receptor. The Cbl-binduced increase in proliferation is approximately equivalent to that achieved with co-stimulation. If Cbl-b is directly linked to CD28, co-stimulation should be defective in Cbl-b-deficient T cells. Instead, CD28 enhances proliferation to a similar extent in T cells from both Cbl-b heterozygous and homozygous deficient mice [10, 11] . Further, Chiang et al. [11] found that CD28 can still enhance Vav phosphorylation and Rac1 activation in these cells. Although this augmentation is less evident in Bachmaier et al.'s study [10] , these findings cast some uncertainty as to whether Cbl is directly connected to CD28. If the connection is indeed real, CD28 co-stimulation can only be partially dependent on the protein. These observations, combined with the finding that CD28 co-stimulation is normal in Vav-deficient T cells [13] , are more supportive of a connection with T-cell receptor signaling, which may then provide Cbl-dependent signals that cooperate with CD28 to generate optimal signaling in T cells.
Further work will obviously be needed to clarify the connection between Cbl-b and T-cell receptor and CD28 signaling. These new studies, however, point to an exciting new advance in our understanding of how the selective destruction of intracellular proteins by Cbl-b can regulate the threshold of lymphocyte receptor signaling and the onset of autoimmunity. 
